Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The endoplasmic reticulum is a target organelle for trivalent dimethylarsinic acid (DMAIII)-induced cytotoxicity.

Toxicology and applied pharmacology·2012

Same author

(E)-1-{4-[Bis(4-bromo-phen-yl)meth-yl]piperazin-1-yl}-3-(4-eth-oxy-phen-yl)prop-2-en-1-one.

Acta crystallographica. Section E, Structure reports online·2012

Same author

(E)-1-{4-[Bis(4-bromo-phen-yl)meth-yl]piperazin-1-yl}-3-(4-methyl-phen-yl)prop-2-en-1-one.

Acta crystallographica. Section E, Structure reports online·2012

Same author

(E)-3-(1,3-Benzodioxol-5-yl)-1-{4-[bis-(4-meth-oxy-phen-yl)meth-yl]piperazin-1-yl}prop-2-en-1-one.

Acta crystallographica. Section E, Structure reports online·2012

Same author

Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting.

PloS one·2012

Same author

Metabolism studies of casticin in rats using HPLC-ESI-MS(n).

Biomedical chromatography : BMC·2012

Search research articles

Related Experiment Video

Updated: Jun 25, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

A comprehensive review on ziconotide.

Jinping Lin¹, Shuwei Chen², Usman Dawood Butt³

¹Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China.

|May 23, 2024

Summary

Ziconotide offers potent analgesia for severe chronic pain by blocking N-type calcium channels. However, its use is limited by administration route and side effects, prompting research into improved delivery and drug analogs.

Keywords:

Controversies Intrathecal administration strategies N-type calcium channel blocker Pain management

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Genome Editing with CompoZr Custom Zinc Finger Nucleases ZFNs

Genome Editing with CompoZr Custom Zinc Finger Nucleases ZFNs

Published on: June 14, 2012

Related Experiment Videos

Last Updated: Jun 25, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Genome Editing with CompoZr Custom Zinc Finger Nucleases ZFNs

Genome Editing with CompoZr Custom Zinc Finger Nucleases ZFNs

Published on: June 14, 2012

Area of Science:

Pharmacology
Neuroscience
Pain Management

Background:

Severe chronic pain management remains a significant public health challenge with limited treatment options.
Ziconotide, a synthetic peptide from *Conus magus*, is a first-line intrathecal treatment for refractory severe chronic pain.
It acts by blocking spinal N-type calcium channels, inhibiting pain neurotransmitter release.

Purpose of the Study:

To provide a comprehensive review of intrathecal ziconotide's pharmacokinetics and metabolism.
To summarize strategies for enhancing ziconotide's clinical efficacy and reducing side effects.
To explore structural modifications and future developments in N-type calcium channel blockers.

Main Methods:

Literature review of pharmacokinetic and metabolism studies.
Analysis of clinical data on ziconotide efficacy and adverse events.
Exploration of ongoing research in drug design and delivery systems.

Main Results:

Ziconotide provides potent analgesia without tolerance, respiratory depression, or withdrawal.
Intrathecal administration and dose-related CNS side effects limit its application.
Research is focused on optimizing delivery and developing novel analogs.

Conclusions:

Ziconotide is an effective intrathecal analgesic but requires careful management due to side effects.
Further research into ziconotide pharmacokinetics, metabolism, and structural analogs is crucial.
Developing new selective N-type calcium channel blockers holds promise for improved pain management.